CN111568846A - 一种抗痤疮制剂 - Google Patents
一种抗痤疮制剂 Download PDFInfo
- Publication number
- CN111568846A CN111568846A CN202010649441.XA CN202010649441A CN111568846A CN 111568846 A CN111568846 A CN 111568846A CN 202010649441 A CN202010649441 A CN 202010649441A CN 111568846 A CN111568846 A CN 111568846A
- Authority
- CN
- China
- Prior art keywords
- skin
- acne
- prebiotics
- oligosaccharide
- sebum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003255 anti-acne Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 235000020242 coleus extract Nutrition 0.000 claims abstract description 12
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000008591 skin barrier function Effects 0.000 claims abstract description 9
- 229940122511 Sebum inhibitor Drugs 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 5
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 5
- 239000011570 nicotinamide Substances 0.000 claims abstract description 5
- 229940075999 phytosterol ester Drugs 0.000 claims abstract description 5
- 239000003974 emollient agent Substances 0.000 claims abstract description 4
- 239000002562 thickening agent Substances 0.000 claims abstract description 4
- 239000003755 preservative agent Substances 0.000 claims abstract description 3
- 230000002335 preservative effect Effects 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940049964 oleate Drugs 0.000 claims description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- 229930182558 Sterol Natural products 0.000 claims description 3
- 229940064062 alpha-glucan oligosaccharide Drugs 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- 235000003702 sterols Nutrition 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000019493 Macadamia oil Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 239000010469 macadamia oil Substances 0.000 claims description 2
- -1 sterol acetate Chemical class 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 26
- 206010000496 acne Diseases 0.000 abstract description 26
- 241000186427 Cutibacterium acnes Species 0.000 abstract description 14
- 229940055019 propionibacterium acne Drugs 0.000 abstract description 14
- 241000191963 Staphylococcus epidermidis Species 0.000 abstract description 13
- 241000894006 Bacteria Species 0.000 abstract description 9
- 210000002374 sebum Anatomy 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract description 3
- 230000037380 skin damage Effects 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 239000002085 irritant Substances 0.000 abstract description 2
- 231100000021 irritant Toxicity 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000007480 spreading Effects 0.000 abstract description 2
- 238000003892 spreading Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 28
- 239000006041 probiotic Substances 0.000 description 11
- 235000018291 probiotics Nutrition 0.000 description 11
- 230000003385 bacteriostatic effect Effects 0.000 description 9
- 210000004907 gland Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241000131459 Plectranthus barbatus Species 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- XXBAQTDVRLRXEV-UHFFFAOYSA-N 3-tetradecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCOCCCO XXBAQTDVRLRXEV-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 235000021508 Coleus Nutrition 0.000 description 1
- 235000005320 Coleus barbatus Nutrition 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000208467 Macadamia Species 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 229930192650 Santalin Natural products 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 1
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940116987 ppg-3 myristyl ether Drugs 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical group OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公布了一种抗痤疮制剂，包含以下质量百分比的各组分：油溶性毛喉鞘蕊提取物1~5%，皮脂抑制剂1~10%，益生元0.5~5%，皮肤屏障功能修复剂0.5~5%，皮肤调理剂0.5~5%，润肤剂10~20%，增稠剂0.1~0.5%，防腐剂0.1~1%，水余量。本发明将毛喉鞘蕊提取物作为抗菌剂，有效抑制痤疮丙酸杆菌、金黄色葡萄球菌、表皮葡萄球菌等皮肤病原体大量繁殖；以聚季铵盐‑22和烟酰胺作为皮脂抑制剂，减少皮脂分泌和痤疮的扩散范围；通过益生元选择性地促进有益菌的代谢和增殖，平衡皮肤的微生物群；植物甾醇酯作为皮肤屏障功能修复剂，促进痤疮快速收口，修复痤疮皮损，缓解炎症反应，温和无刺激。
Description
技术领域
本发明属于皮肤护理技术领域，特别是涉及一种抗痤疮制剂。
背景技术
痤疮是一种皮肤无法正常排泄油脂而引发的一连串炎症反应，是毛囊皮脂腺组织的慢性炎症性皮肤症状，主要发于颜面、胸背等皮脂分泌旺盛部位，临床表现为粉刺、炎性丘疹、脓包、结节、囊肿等多形性皮损。痤疮的发病机制较为复杂，主要与皮脂分泌增加、毛囊皮脂腺导管化异常、微生物在毛囊皮脂腺内定植、内分泌等有关。
毛囊皮脂腺中的微生物在痤疮发病过程中起重要作用，丙酸杆菌是毛囊皮脂腺内数量最多的微生物，与痤疮的发病密切相关。其中，痤疮丙酸杆菌的作用最为关键，是痤疮患者毛囊皮脂腺内优势菌群，占所有检测到微生物数量的89％。除了痤疮丙酸杆菌以外，还包括金黄色葡萄球菌、表皮葡萄球菌、马拉色菌等。表皮葡萄球菌是一种凝固酶阴性的革兰氏阳性菌，在痤疮患者毛囊皮脂腺内定植的微生物中占6.8～47.3％，仅次于痤疮丙酸杆菌。
痤疮的治疗目前多以药物治疗为主，局部治疗中以维A酸类药物与抗菌药物联用，如全反式维A酸、阿达帕林与他扎罗汀治疗轻度痤疮；口服治疗药物中维A酸类药物主要用于重度痤疮，口服抗菌药物适用于中、重度痤疮患者，但都存在潜在安全问题，需严格控制使用剂量，因此，开发一种无耐药性、具有皮肤屏障修护功能的抗痤疮制剂具有重要意义。
发明内容
本发明的目的是为了克服现有技术中存在的不足，提供一种具有皮肤屏障修护功能，可以缓解炎症反应，调节毛囊皮脂腺微生态，温和无刺激的抗痤疮制剂。
本发明为实现上述目的，采用如下技术方案：
一种抗痤疮制剂，其特征在于，包含以下质量百分比的各组分：油溶性毛喉鞘蕊提取物1～5％，皮脂抑制剂1～10％，益生元0.5～5％，皮肤屏障功能修复剂0.5～5％，皮肤调理剂0.5～5％，润肤剂10～20％，增稠剂0.1～0.5％，防腐剂0.1～1％，水余量。
毛喉鞘蕊系唇形科鞘蕊花属植物，具有强心、降压、平喘、抗血栓及降低眼内压等药理作用，现临床上开始用于心脑血管病、肿瘤和老年常患疾病等的治疗。毛喉鞘蕊提取物中含有α-雪松醇、福司可林、美迪紫檀素、β-谷甾醇、愈创木酚甘油醚、齐墩果酸、2-呋喃甲酸、乙酸龙脑酯等成分，具有抗菌、消炎、镇静等生物学益处，能有效抑制痤疮丙酸杆菌、金黄色葡萄球菌、表皮葡萄球菌等皮肤病原体大量繁殖，修复肌肤受损组织，可以预防或缓解痤疮症状。
其进一步特征在于：所述皮脂抑制剂为聚季铵盐-22和烟酰胺。
聚季铵盐-22可以使皮肤变得更亲脂，减小皮肤的表面张力，从而使分泌出来的皮脂在皮肤表面的扩散速度明显减慢，虽然没有直接减少皮脂的量，但可以减少痤疮的扩散范围。
烟酰胺可以抑制皮脂腺细胞以葡萄糖为底物合成脂质的反应，特异性抑制脂肪酸和三酰甘油合成，减少皮脂分泌，防止毛囊阻塞，避免痤疮丙酸杆菌大量繁殖。同时，其化学结构上含有吡啶环，对痤疮丙酸杆菌及皮脂产物刺激引起的白细胞趋化活性有抑制作用，可有效治疗痤疮。
进一步的：所述益生元为菊粉、α-葡聚糖寡糖、低聚果糖、低聚异麦芽糖、低聚半乳糖、低聚木糖中的至少一种。
益生元是不被宿主消化吸收、选择性促进一种或多种益生菌代谢和增殖的有机物质。益生菌群的生长对人体皮肤具有多重作用，首先，益生菌会参与皮肤皮脂腺代谢，形成一层乳化脂质膜，这层脂质膜由游离脂肪酸构成，它可以中和沾染皮肤上的碱性物质，抑制暂住菌、真菌等致病微生物的定植、生长和繁殖，对皮肤自净起重要作用。其次，有层次并且有序地定植在皮肤上的益生菌群，尤如一层生物膜，不仅对机体裸露的表皮起了占位保护作用，而且与其他菌群彼此相互依赖、相互制约，形成一个相互稳定相互和谐的生物屏障，提高皮肤免疫功能，保护机体的健康。第三，皮肤表面的益生菌生长会分解产生磷脂、固醇类、角质蛋白等成分，可以被皮肤细胞吸收，促进皮肤细胞生长，延缓老化和减少皱纹产生。
当皮肤环境微生态改变时，有害菌会大量繁殖并取代益生菌的位置，使益生菌数量减少，菌群失调，皮肤的第一道屏障被破坏，皮肤会出现红肿、炎症等症状。益生元不被有害菌利用，能够选择性地促进有益菌的代谢和增殖，强化益生菌群，与杀菌剂同时使用时，对益生菌起到竞争性保护作用，形成皮肤保护屏障，阻止有害菌的入侵，减少痤疮再次出现的几率。此外，在重新平衡皮肤的微生物群时，还能提供良好的皮肤保湿功效。
所述皮肤屏障功能修复剂为大豆甾醇乙酸酯、植物甾醇澳洲坚果油酸酯、植物甾醇油酸酯中的至少一种植物甾醇酯。
大豆甾醇乙酸酯、植物甾醇澳洲坚果油酸酯、植物甾醇油酸酯都是植物甾醇酯，由植物甾醇酯化改性所得，具有良好的油溶性和较强的渗透性、抗氧化性、抗炎性，能到达真表皮连接层，维持细胞的柔软和湿润，保持皮肤表面水份，促进皮肤新陈代谢，改善肌肤的结构和功能，促进痤疮快速收口，修复痤疮的皮损，进而防止瘢痕产生。
所述皮肤调理剂为红没药醇、燕麦仁提取物、玉米须丝提取物、尿囊素等成分。
所述润肤剂为霍霍巴籽油、野大豆油、PPG-3肉豆蔻醇醚、丁二醇等。
所述增稠剂为紫虫胶、黄原胶等。
上述的抗痤疮制剂可用于制备治疗痤疮的膜剂、软膏剂、粉剂等产品中。
与现有技术相比，本发明的优点在于：本发明将毛喉鞘蕊提取物作为抗菌剂，有效抑制痤疮丙酸杆菌、金黄色葡萄球菌、表皮葡萄球菌等皮肤病原体大量繁殖；以聚季铵盐-22和烟酰胺作为皮脂抑制剂，减少皮脂分泌和痤疮的扩散范围；通过益生元选择性地促进有益菌的代谢和增殖，平衡皮肤的微生物群；植物甾醇酯作为皮肤屏障功能修复剂，促进痤疮快速收口，修复痤疮皮损，缓解炎症反应，温和无刺激。
附图说明
图1为本发明高效消毒剂抑菌效果示意图。
其中图1(a)为水溶性毛喉鞘蕊提取物对表皮葡萄球菌的抑菌效果，图1(b)为油溶性毛喉鞘蕊提取物对表皮葡萄球菌的抑菌效果，图1(c)为水溶性毛喉鞘蕊提取物对痤疮丙酸杆菌的抑菌效果，图1(d)为油溶性毛喉鞘蕊提取物对痤疮丙酸杆菌的抑菌效果。1～6分别为实施例1～6。
具体实施方式
以下结合实施例对本发明作进一步详细描述，所述实施例只用于解释本发明，并非用于限定本发明的范围。下述实施例中所用的试验方法如无特殊说明，均为常规方法；所用的材料、试剂等，如无特殊说明，为可从商业途径得到的试剂和材料。以下各组分为含量为质量百分比。
实施例1
实施例2
实施例3
实施例4
实施例5
实施例6
1、采用本发明所制备的抗痤疮制剂抑菌效果评价：
将表皮葡萄球菌CMCC 26069、痤疮丙酸杆菌ATCC 6919进行活化，取4～8代新鲜斜面培养物，用pH7.2的PBS将菌苔洗下，用紫外分光光度计调节，使菌悬液OD600＝0.5。取100μL10倍稀释的菌悬液涂布琼脂平板，干燥后等间距放上药敏试纸，滴加10μL实施例1～6中配制的抗痤疮制剂，37℃培养24～48h，观察抑菌效果，见图1。
从图1(a)(c)中可以看出，实施例1～3对表皮葡萄球菌、痤疮丙酸杆菌无明显抑菌效果。从图1(b)(d)中可以看出，实施例4～6对表皮葡萄球菌、痤疮丙酸杆菌均有明显的抑菌效果。当抗痤疮制剂中油溶性毛喉鞘蕊提取物含量大于1％时，对表皮葡萄球菌、痤疮丙酸杆菌有显著的抑菌效果，并且随着油溶性毛喉鞘蕊提取物含量增加，抑菌效果也增强。
2、竞争性生长测试
将菌悬液OD600＝0.5的嗜酸乳杆菌、表皮葡萄球菌/金黄色葡萄球菌，按10％接种量接种至含1％益生元(菊粉和α-葡聚糖寡糖)的胰蛋白胨大豆肉汤中，37℃培养24h，然后进行平板计数，评价益生元在益生菌(嗜酸乳杆菌)与病原菌(表皮葡萄球菌/金黄色葡萄球菌)同时存在时对菌群生长的影响，见表1。从表中可以看出，益生元能促进益生菌的生长，但对病原菌无促进作用。
表1竞争性生长结果
Claims (4)
1.一种抗痤疮制剂，其特征在于，包含以下质量百分比的各组分：油溶性毛喉鞘蕊提取物1~5%，皮脂抑制剂1~10%，益生元0.5~5%，皮肤屏障功能修复剂0.5~5%，皮肤调理剂0.5~5%，润肤剂10~20%，增稠剂0.1~0.5%，防腐剂0.1~1%，水余量。
2.如权利要求1所述的抗痤疮制剂，其特征在于：所述皮脂抑制剂为聚季铵盐-22和烟酰胺。
3.如权利要求1或2所述的抗痤疮制剂，其特征在于：所述益生元为菊粉、α-葡聚糖寡糖、低聚果糖、低聚异麦芽糖、低聚半乳糖、低聚木糖中的至少一种。
4.如权利要求1或2所述的抗痤疮制剂，其特征在于：所述皮肤屏障功能修复剂为大豆甾醇乙酸酯、植物甾醇澳洲坚果油酸酯、植物甾醇油酸酯中的至少一种植物甾醇酯。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010649441.XA CN111568846A (zh) | 2020-07-08 | 2020-07-08 | 一种抗痤疮制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010649441.XA CN111568846A (zh) | 2020-07-08 | 2020-07-08 | 一种抗痤疮制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111568846A true CN111568846A (zh) | 2020-08-25 |
Family
ID=72110148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010649441.XA Pending CN111568846A (zh) | 2020-07-08 | 2020-07-08 | 一种抗痤疮制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111568846A (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113493487A (zh) * | 2021-04-29 | 2021-10-12 | 深圳海创生物科技有限公司 | 一种化合物和组合物及其在制备促进益生菌增殖和/或抑制有害菌生长的产品中的应用 |
| CN113576943A (zh) * | 2021-07-09 | 2021-11-02 | 中山大学 | 一种益生元发酵物及其制备方法与应用 |
| EP3973971A1 (de) * | 2020-09-28 | 2022-03-30 | Medice Arzneimittel Pütter GmbH & Co. KG | Probiotische pharmazeutische zusammensetzung |
| CN114645002A (zh) * | 2022-04-29 | 2022-06-21 | 廖梅香 | 一种用于皮肤抗炎和治疗痤疮的副干酪乳杆菌及其应用 |
| CN115969752A (zh) * | 2023-01-19 | 2023-04-18 | 广州环亚化妆品科技股份有限公司 | 无患子发酵物在调节皮肤微生态平衡中的应用 |
| CN117860649A (zh) * | 2024-03-08 | 2024-04-12 | 珠海金肽生物科技有限公司 | 一种调节皮肤微生态和修复肌肤屏障的组合物及应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020160066A1 (en) * | 2001-02-20 | 2002-10-31 | Muhammed Majeed | Composition and methods containing an antimicrobial essential oil extracted from Coleus forskohlii |
| CN107412045A (zh) * | 2017-05-19 | 2017-12-01 | 广州蜜妆生物科技有限公司 | 一种益生元健肤面膜 |
| CN111374896A (zh) * | 2018-12-28 | 2020-07-07 | 西安臻瑞生物科技有限公司 | 一种治疗痤疮的益生元和益生菌护肤品及其制备方法 |
-
2020
- 2020-07-08 CN CN202010649441.XA patent/CN111568846A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020160066A1 (en) * | 2001-02-20 | 2002-10-31 | Muhammed Majeed | Composition and methods containing an antimicrobial essential oil extracted from Coleus forskohlii |
| CN107412045A (zh) * | 2017-05-19 | 2017-12-01 | 广州蜜妆生物科技有限公司 | 一种益生元健肤面膜 |
| CN111374896A (zh) * | 2018-12-28 | 2020-07-07 | 西安臻瑞生物科技有限公司 | 一种治疗痤疮的益生元和益生菌护肤品及其制备方法 |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3973971A1 (de) * | 2020-09-28 | 2022-03-30 | Medice Arzneimittel Pütter GmbH & Co. KG | Probiotische pharmazeutische zusammensetzung |
| CN113493487A (zh) * | 2021-04-29 | 2021-10-12 | 深圳海创生物科技有限公司 | 一种化合物和组合物及其在制备促进益生菌增殖和/或抑制有害菌生长的产品中的应用 |
| CN113493487B (zh) * | 2021-04-29 | 2022-05-17 | 深圳海创生物科技有限公司 | 一种化合物和组合物及其在制备促进益生菌增殖和/或抑制有害菌生长的产品中的应用 |
| CN113576943A (zh) * | 2021-07-09 | 2021-11-02 | 中山大学 | 一种益生元发酵物及其制备方法与应用 |
| CN114645002A (zh) * | 2022-04-29 | 2022-06-21 | 廖梅香 | 一种用于皮肤抗炎和治疗痤疮的副干酪乳杆菌及其应用 |
| CN115969752A (zh) * | 2023-01-19 | 2023-04-18 | 广州环亚化妆品科技股份有限公司 | 无患子发酵物在调节皮肤微生态平衡中的应用 |
| CN115969752B (zh) * | 2023-01-19 | 2024-03-01 | 广州环亚化妆品科技股份有限公司 | 无患子发酵物在调节皮肤微生态平衡中的应用 |
| CN117860649A (zh) * | 2024-03-08 | 2024-04-12 | 珠海金肽生物科技有限公司 | 一种调节皮肤微生态和修复肌肤屏障的组合物及应用 |
| CN117860649B (zh) * | 2024-03-08 | 2024-08-30 | 珠海金肽生物科技有限公司 | 一种调节皮肤微生态和修复肌肤屏障的组合物及应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111568846A (zh) | 一种抗痤疮制剂 | |
| US10449222B2 (en) | Method for preventing and/or treating infections, colonisations, or illnesses related to Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes, Enterococcus faecium, Enterobacter cloacae, Proteus mirabilis, Bacteroides fragilis, Staphylococcus epidermidis, Propionibacterium acnes, Candida albicans and/or Malassezia furfur | |
| Shu et al. | Preparation of shikonin liposome and evaluation of its in vitro antibacterial and in vivo infected wound healing activity | |
| EP2836223B1 (en) | Method of repairing skin using Lactobacillus rhamnosus GG | |
| JP4678896B2 (ja) | 微生物感染を予防または制御するための共生Ｂａｃｉｌｌｕｓ芽胞の局所的使用 | |
| USRE46718E1 (en) | Compositions comprising Lactobacillus plantarum strains in combination with tannin and new Lactobacillus plantarum strains | |
| TWI750716B (zh) | 皮膚外用組成物及其用於製備改善皮膚疾病及皮膚發炎之組成物的用途 | |
| Peng et al. | Polyphenols and tri-terpenoids from Olea europaea L. in alleviation of enteric pathogen infections through limiting bacterial virulence and attenuating inflammation | |
| JP2019509312A (ja) | ガードネレラ・バギナリスによる細菌腟感染症及び存在する場合には併発真菌感染症を治療するための乳酸菌組成物 | |
| CN118879590B (zh) | 一种防治细菌性阴道炎的嗜酸乳杆菌sy23及其应用 | |
| Yin et al. | Topical probiotics in wound care: a review of effects, mechanisms, and applications | |
| CN107735083A (zh) | 抗菌组合物 | |
| Muhsinin et al. | Formulation and Evaluation of a Turmeric Kombucha Facial Toner with Potential as an Anti-Acne Agent. | |
| CN111374896A (zh) | 一种治疗痤疮的益生元和益生菌护肤品及其制备方法 | |
| KR102545060B1 (ko) | 천연소재 발효추출물을 유효성분으로 함유하는 여드름 개선용 화장료 조성물 | |
| KR20120061221A (ko) | 붉나무, 지모, 가죽나무 추출물과 그 용도 | |
| CN119530099A (zh) | 一种对皮肤有益的青春双歧杆菌及其衍生物和应用 | |
| CN116531547B (zh) | 一种雪松植萃抗敏修复精华液一次性卫生用品护理基材、制备方法及应用 | |
| US20230218666A1 (en) | Antimicrobial combinations | |
| CN114053318A (zh) | 菌群调节用组合物 | |
| US12194068B2 (en) | Dietary supplement composition for treating and managing acne | |
| US20230115784A1 (en) | Compositions and methods for treating acne vulgaris | |
| CN119280328A (zh) | 一种防治痤疮的组合物及其应用 | |
| Wang et al. | Multi-strain fermentation amplifies antioxidant and hepatoprotective efficacy of shiitake mushroom (Lentinus edodes) broth: A dual approach targeting oxidative stress and acute alcohol injury | |
| Natanzi et al. | Effects of the Aqueous Extract of Curcuma longa on Pathogenic Gastrointestinal and Probiotic Bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200825 |